These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
226 related articles for article (PubMed ID: 7995998)
1. Antibodies inhibiting Trypanosoma cruzi trans-sialidase activity in sera from human infections. Leguizamón MS; Campetella O; Russomando G; Almiron M; Guillen I; Ganzález Cappa SM; Frasch AC J Infect Dis; 1994 Dec; 170(6):1570-4. PubMed ID: 7995998 [TBL] [Abstract][Full Text] [Related]
2. Enzyme-linked immunoassay using recombinant trans-sialidase of Trypanosoma cruzi can be employed for monitoring of patients with Chagas' disease after drug treatment. Pereira-Chioccola VL; Fragata-Filho AA; Levy AM; Rodrigues MM; Schenkman S Clin Diagn Lab Immunol; 2003 Sep; 10(5):826-30. PubMed ID: 12965912 [TBL] [Abstract][Full Text] [Related]
3. Diagnostic Applicability of Neutralizing Antibodies to Trypanosoma cruzi Trans-sialidase. Leguizamón MS Methods Mol Biol; 2019; 1955():239-246. PubMed ID: 30868532 [TBL] [Abstract][Full Text] [Related]
4. trans-sialidase inhibition assay, a highly sensitive and specific diagnostic test for Chagas' disease. Buchovsky AS; Campetella O; Russomando G; Franco L; Oddone R; Candia N; Luquetti A; Gonzalez Cappa SM; Leguizamon MS Clin Diagn Lab Immunol; 2001 Jan; 8(1):187-9. PubMed ID: 11139217 [TBL] [Abstract][Full Text] [Related]
6. Long-lasting antibodies detected by a trans-sialidase inhibition assay of sera from parasite-free, serologically cured chagasic patients. Leguizamón MS; Russomando G; Luquetti A; Rassi A; Almirón M; González-Cappa SM; Frasch AC; Campetella O J Infect Dis; 1997 May; 175(5):1272-5. PubMed ID: 9129103 [TBL] [Abstract][Full Text] [Related]
7. Immune system pathogenesis is prevented by the neutralization of the systemic trans-sialidase from Trypanosoma cruzi during severe infections. Risso MG; Pitcovsky TA; Caccuri RL; Campetella O; Leguizamón MS Parasitology; 2007 Apr; 134(Pt 4):503-10. PubMed ID: 17166319 [TBL] [Abstract][Full Text] [Related]
8. Sera from chronic Chagasic patients and rodents infected with Trypanosoma cruzi inhibit trans-sialidase by recognizing its amino-terminal and catalytic domain. Pereira-Chioccola VL; Schenkman S; Kloetzel JK Infect Immun; 1994 Jul; 62(7):2973-8. PubMed ID: 8005683 [TBL] [Abstract][Full Text] [Related]
9. Diagnosis of congenital Trypanosoma cruzi infection: A serologic test using Shed Acute Phase Antigen (SAPA) in mother-child binomial samples. Volta BJ; Russomando G; Bustos PL; Scollo K; De Rissio AM; Sánchez Z; Cardoni RL; Bua J Acta Trop; 2015 Jul; 147():31-7. PubMed ID: 25847262 [TBL] [Abstract][Full Text] [Related]
10. Trypanosoma cruzi trans-sialidase: enhancement of virulence in a murine model of Chagas' disease. Chuenkova M; Pereira ME J Exp Med; 1995 May; 181(5):1693-703. PubMed ID: 7722448 [TBL] [Abstract][Full Text] [Related]
11. Efficacy of a trans-sialidase-ISCOMATRIX subunit vaccine candidate to protect against experimental Chagas disease. Bontempi IA; Vicco MH; Cabrera G; Villar SR; González FB; Roggero EA; Ameloot P; Callewaert N; Pérez AR; Marcipar IS Vaccine; 2015 Mar; 33(10):1274-83. PubMed ID: 25625671 [TBL] [Abstract][Full Text] [Related]
12. Use of Trypanosoma cruzi purified glycoprotein (GP57/51) or trypomastigote-shed antigens to assess cure for human Chagas' disease. Gazzinelli RT; Galvao LM; Krautz G; Lima PC; Cancado JR; Scharfstein J; Krettli AU Am J Trop Med Hyg; 1993 Nov; 49(5):625-35. PubMed ID: 8250103 [TBL] [Abstract][Full Text] [Related]
13. Trypanosoma cruzi trans-sialidase in complex with a neutralizing antibody: structure/function studies towards the rational design of inhibitors. Buschiazzo A; Muiá R; Larrieux N; Pitcovsky T; Mucci J; Campetella O PLoS Pathog; 2012 Jan; 8(1):e1002474. PubMed ID: 22241998 [TBL] [Abstract][Full Text] [Related]
14. Trans-sialidase, SAPA amino acid repeats and the relationship between Trypanosoma cruzi and the mammalian host. Frasch AC Parasitology; 1994; 108 Suppl():S37-44. PubMed ID: 8084653 [TBL] [Abstract][Full Text] [Related]
15. Shift of excretory-secretory immunogens of Trypanosoma cruzi during human Chagas' disease. Jazín EE; Luquetti AO; Rassi A; Frasch AC Infect Immun; 1991 Jun; 59(6):2189-91. PubMed ID: 1903775 [TBL] [Abstract][Full Text] [Related]
17. Mice infected with Trypanosoma cruzi produce antibodies against the enzymatic domain of trans-sialidase that inhibit its activity. Leguizamón MS; Campetella OE; González Cappa SM; Frasch AC Infect Immun; 1994 Aug; 62(8):3441-6. PubMed ID: 8039915 [TBL] [Abstract][Full Text] [Related]
18. The repetitive domain of Trypanosoma cruzi trans-sialidase enhances the immune response against the catalytic domain. Buscaglia CA; Campetella O; Leguizamón MS; Frasch AC J Infect Dis; 1998 Feb; 177(2):431-6. PubMed ID: 9466532 [TBL] [Abstract][Full Text] [Related]
19. Thymocyte depletion in Trypanosoma cruzi infection is mediated by trans-sialidase-induced apoptosis on nurse cells complex. Mucci J; Hidalgo A; Mocetti E; Argibay PF; Leguizamon MS; Campetella O Proc Natl Acad Sci U S A; 2002 Mar; 99(6):3896-901. PubMed ID: 11891302 [TBL] [Abstract][Full Text] [Related]
20. The trans-sialidase, the major Trypanosoma cruzi virulence factor: Three decades of studies. Freire-de-Lima L; Fonseca LM; Oeltmann T; Mendonça-Previato L; Previato JO Glycobiology; 2015 Nov; 25(11):1142-9. PubMed ID: 26224786 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]